iRECIST Guideline Unveiled for Immunotherapies.

abstract：:E3 ubiquitin ligases are of interest as drug targets for their ability to regulate protein stability and function. The oncogene Mdm2 is an attractive E3 ligase to target, as it is the key negative regulator of the tumor suppressor p53, which controls the transcription of genes involved in cell fate. Overexpression of ...

journal_title：Cancer discovery

authors： Herman AG,Hayano M,Poyurovsky MV,Shimada K,Skouta R,Prives C,Stockwell BR

更新日期：2011-09-01 00:00:00

abstract：:Nuclear hormone receptor targeting suppresses melanoma progression in diverse preclinical models. ...

journal_title：Cancer discovery

authors：

更新日期：2014-05-01 00:00:00

abstract：:Pemigatinib was effective in patients with cholangiocarcinomas with FGFR2 fusions or rearrangements. ...

journal_title：Cancer discovery

authors：

更新日期：2020-05-01 00:00:00

abstract：:Critically short telomeres activate cellular senescence or apoptosis, as mediated by the tumor suppressor p53, but in the absence of this checkpoint response, telomere dysfunction engenders chromosomal aberrations and cancer. Here, analysis of p53-regulated genes activated in the setting of telomere dysfunction identi...

journal_title：Cancer discovery

authors： Zhang Y,Shin SJ,Liu D,Ivanova E,Foerster F,Ying H,Zheng H,Xiao Y,Chen Z,Protopopov A,Depinho RA,Paik JH

更新日期：2013-07-01 00:00:00

abstract：:The quest for tumor-associated antigens (TAA) and neoantigens is a major focus of cancer immunotherapy. Here, we combine a neoantigen prediction pipeline and human leukocyte antigen (HLA) peptidomics to identify TAAs and neoantigens in 16 tumors derived from seven patients with melanoma and characterize their interact...

journal_title：Cancer discovery

authors： Kalaora S,Wolf Y,Feferman T,Barnea E,Greenstein E,Reshef D,Tirosh I,Reuben A,Patkar S,Levy R,Quinkhardt J,Omokoko T,Qutob N,Golani O,Zhang J,Mao X,Song X,Bernatchez C,Haymaker C,Forget MA,Creasy C,Greenberg P,

更新日期：2018-11-01 00:00:00

abstract：:Clinically relevant subtypes exist for pancreatic ductal adenocarcinoma (PDAC), but molecular characterization is not yet standard in clinical care. We implemented a biopsy protocol to perform time-sensitive whole-exome sequencing and RNA sequencing for patients with advanced PDAC. Therapeutically relevant genomic alt...

journal_title：Cancer discovery

authors： Aguirre AJ,Nowak JA,Camarda ND,Moffitt RA,Ghazani AA,Hazar-Rethinam M,Raghavan S,Kim J,Brais LK,Ragon D,Welch MW,Reilly E,McCabe D,Marini L,Anderka K,Helvie K,Oliver N,Babic A,Da Silva A,Nadres B,Van Seventer EE,

更新日期：2018-09-01 00:00:00

abstract：:To investigate immune escape during breast tumor progression, we analyzed the composition of leukocytes in normal breast tissues, ductal carcinoma in situ (DCIS), and invasive ductal carcinomas (IDC). We found significant tissue and tumor subtype-specific differences in multiple cell types including T cells and neutro...

journal_title：Cancer discovery

authors： Gil Del Alcazar CR,Huh SJ,Ekram MB,Trinh A,Liu LL,Beca F,Zi X,Kwak M,Bergholtz H,Su Y,Ding L,Russnes HG,Richardson AL,Babski K,Min Hui Kim E,McDonnell CH 3rd,Wagner J,Rowberry R,Freeman GJ,Dillon D,Sorlie T,Cous

更新日期：2017-10-01 00:00:00

abstract：:A multidisciplinary panel of experts has issued guidelines that consolidate current evidence on testing for molecular biomarkers in colorectal cancer. The guidelines aim to standardize molecular testing for patients with colorectal cancer and help clinicians identify patients most likely to benefit from targeted treat...

journal_title：Cancer discovery

authors：

更新日期：2017-04-01 00:00:00

abstract：:The EGFR inhibitor osimertinib may be an effective therapy for patients with untreated non-small cell lung cancer who have brain metastases. In a recent study, the drug extended median progression-free survival and increased objective response rates compared with the first-generation EGFR inhibitors gefitinib and erlo...

journal_title：Cancer discovery

authors：

更新日期：2018-11-01 00:00:00

abstract：:Biotechnology startup Arvinas is developing proteolysis-targeting chimeras (PROTAC) that combat cancer by degrading disease-causing proteins. The company's first PROTACs will target prostate and breast cancers, and a recent deal with Pfizer will allow Arvinas to develop PROTACs for other cancer types. ...

journal_title：Cancer discovery

authors：

更新日期：2018-04-01 00:00:00

abstract：:The NCI and Department of Veterans Affairs (VA) are collaborating on the NCI and VA Interagency Group to Accelerate Trials Enrollment, or NAVIGATE, which will launch at 12 VA facilities across the country. The program aims to increase participation of veterans with cancer in NCI-sponsored clinical trials. ...

journal_title：Cancer discovery

authors：

更新日期：2018-08-01 00:00:00

abstract：:Protein-coding mutations in clear cell renal cell carcinoma (ccRCC) have been extensively characterized, frequently involving inactivation of the von Hippel-Lindau (VHL) tumor suppressor. Roles for noncoding cis-regulatory aberrations in ccRCC tumorigenesis, however, remain unclear. Analyzing 10 primary tumor/normal p...

journal_title：Cancer discovery

authors： Yao X,Tan J,Lim KJ,Koh J,Ooi WF,Li Z,Huang D,Xing M,Chan YS,Qu JZ,Tay ST,Wijaya G,Lam YN,Hong JH,Lee-Lim AP,Guan P,Ng MSW,He CZ,Lin JS,Nandi T,Qamra A,Xu C,Myint SS,Davies JOJ,Goh JY,Loh G,Tan BC,Roz

更新日期：2017-11-01 00:00:00

abstract：UNLABELLED:Targeted molecular therapy has yielded remarkable outcomes in certain cancers, but specific therapeutic targets remain elusive for many others. As a result of two independent RNA interference (RNAi) screens, we identified pathway dependence on a member of the Janus-activated kinase (JAK) tyrosine kinase fami...

journal_title：Cancer discovery

authors： Sanda T,Tyner JW,Gutierrez A,Ngo VN,Glover J,Chang BH,Yost A,Ma W,Fleischman AG,Zhou W,Yang Y,Kleppe M,Ahn Y,Tatarek J,Kelliher MA,Neuberg DS,Levine RL,Moriggl R,Müller M,Gray NS,Jamieson CH,Weng AP,Staudt LM

更新日期：2013-05-01 00:00:00

abstract：:In this issue of Cancer Discovery, Poulin and colleagues apply structural, biochemical, and biological profiling of two mutants of KRAS, one found most frequently in all cancers (G12D) and one found nearly exclusively in colorectal cancer (A146T). They provide compelling evidence that specific mutations will impart di...

journal_title：Cancer discovery

authors： Hobbs GA,Der CJ

更新日期：2019-06-01 00:00:00

abstract：:As significant increases in the costs of cancer drugs cause financial difficulties for many U.S. patients, some oncologists suggest that changes in pricing policies at the federal and state levels are inevitable. ...

journal_title：Cancer discovery

authors： Bender E

更新日期：2013-08-01 00:00:00

abstract：:IFNγ-producing NK cells induced TME remodeling and orchestrated T cell-mediated tumor control. ...

journal_title：Cancer discovery

authors：

更新日期：2020-12-04 00:00:00

abstract：:Sen and colleagues have shown for the first time the clinical application of an oligonucleotide decoy targeting the oncogenic transcription factor STAT3 for the treatment of head and neck tumors. Intratumoral injection of decoy effectively reduced the activity of STAT3 as evidenced by a decrease in several of its tran...

journal_title：Cancer discovery

authors： Koppikar P,Bromberg J

更新日期：2012-08-01 00:00:00

abstract：:CD10 and GPR77 define a cancer-associated fibroblast (CAF) subset that sustains cancer stemness. ...

journal_title：Cancer discovery

authors：

更新日期：2018-03-01 00:00:00

abstract：:Even in diffuse large B-cell lymphoma (DLBCL), a cancer of professional antigen-presenting cells, response rates to immune checkpoint blockade therapy have been limited. One reason for DLBCL immune evasion is epigenetic repression instead of activation of the antigen-presenting MHC-a dissection of mechanisms underlyin...

journal_title：Cancer discovery

authors： Velcheti V,Wong KK,Saunthararajah Y

更新日期：2019-04-01 00:00:00

abstract：UNLABELLED:B-cell lymphomas frequently contain genomic rearrangements that lead to oncogene activation by heterologous distal regulatory elements. We used a novel approach called "pinpointing enhancer-associated rearrangements by chromatin immunoprecipitation," or PEAR-ChIP, to simultaneously map enhancer activity and ...

journal_title：Cancer discovery

authors： Ryan RJ,Drier Y,Whitton H,Cotton MJ,Kaur J,Issner R,Gillespie S,Epstein CB,Nardi V,Sohani AR,Hochberg EP,Bernstein BE

更新日期：2015-10-01 00:00:00

abstract：:An increasing number of anticancer therapeutic agents target specific mutant proteins that are expressed by many different tumor types. Recent evidence suggests that the selection of patients whose tumors harbor specific genetic alterations identifies the subset of patients who are most likely to benefit from the use ...

journal_title：Cancer discovery

authors： MacConaill LE,Van Hummelen P,Meyerson M,Hahn WC

更新日期：2011-09-01 00:00:00

abstract：:In the ECHO-202/KEYNOTE-037 and ECHO-204 trials reported at the 2017 Annual Meeting of the American Society of Clinical Oncology, patients with squamous cell carcinoma of the head and neck responded well to the combinations of epacadostat plus pembrolizumab and epacadostat plus nivolumab. An IDO1 inhibitor, epacadosta...

journal_title：Cancer discovery

authors：

更新日期：2017-09-01 00:00:00

abstract：:Based on results of the phase III BILCAP study, adjuvant capecitabine should become standard treatment for patients with biliary tract cancer. Among 430 patients who were treated according to the study protocol, capecitabine was associated with a 25% lower risk of death than observation. ...

journal_title：Cancer discovery

authors：

更新日期：2017-07-01 00:00:00

abstract：UNLABELLED:Genetic approaches have shown that the p110β isoform of class Ia phosphatidylinositol-3-kinase (PI3K) is essential for the growth of PTEN-null tumors. Thus, it is desirable to develop p110β-specific inhibitors for cancer therapy. Using a panel of PI3K isoform-specific cellular assays, we screened a collectio...

journal_title：Cancer discovery

authors： Ni J,Liu Q,Xie S,Carlson C,Von T,Vogel K,Riddle S,Benes C,Eck M,Roberts T,Gray N,Zhao J

更新日期：2012-05-01 00:00:00

abstract：:Circadian rhythms integrate many physiological pathways, helping organisms to align the timing of various internal processes to daily cycles in the external environment. Disrupted circadian rhythmicity is a prominent feature of modern society, and has been designated as a probable carcinogen. Here, we review multiple ...

journal_title：Cancer discovery

authors： Pariollaud M,Lamia KA

更新日期：2020-10-01 00:00:00

abstract：:The appearance of a mutant androgen receptor, AR(F876L), in prostate cancer cells chronically exposed to enzalutamide or ARN-509 promotes a switch from antagonist to agonist receptor function, undermining the potential long-term effectiveness of these second-generation antiandrogen drugs. ...

journal_title：Cancer discovery

authors： Nelson WG,Yegnasubramanian S

更新日期：2013-09-01 00:00:00

abstract：:Data from the KEYNOTE-001 trial show that pembrolizumab improves clinical outcomes for patients with advanced non-small cell lung cancer, and is well tolerated. PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy. ...

journal_title：Cancer discovery

authors：

更新日期：2015-06-01 00:00:00

abstract：UNLABELLED:Colorectal cancer was one of the first solid tumors to be classified on the basis of molecular profiling. Microsatellite instability has allowed researchers to distinguish a specific subtype of colorectal cancer that has a clearly identified molecular origin (mismatch repair deficiency), arises on a heredita...

journal_title：Cancer discovery

authors： Vilar E,Tabernero J

更新日期：2013-05-01 00:00:00

abstract：:HDAC inhibitors synergize with PI3K inhibitors to reduce MYC-driven medulloblastoma (MB) growth. ...

journal_title：Cancer discovery

authors：

更新日期：2016-05-01 00:00:00

abstract：:Infant high-grade gliomas appear clinically distinct from their counterparts in older children, indicating that histopathologic grading may not accurately reflect the biology of these tumors. We have collected 241 cases under 4 years of age, and carried out histologic review, methylation profiling, and custom panel, g...

journal_title：Cancer discovery

authors： Clarke M,Mackay A,Ismer B,Pickles JC,Tatevossian RG,Newman S,Bale TA,Stoler I,Izquierdo E,Temelso S,Carvalho DM,Molinari V,Burford A,Howell L,Virasami A,Fairchild AR,Avery A,Chalker J,Kristiansen M,Haupfear K,Dalt

更新日期：2020-07-01 00:00:00